BACKGROUND: Human metapneumovirus (HMPV) causes lower respiratory tract infections in young children. rHMPV-SHs is a recombinant HMPV (rHMPV) based on a biologically derived wild-type HMPV strain. We characterized its infectivity and immunogenicity in healthy adults to determine whether it would be suitable for use as the parent virus for the development of live attenuated rHMPV vaccines. METHODS: Twenty-one healthy adults were inoculated intranasally with 10(6) plaque-forming units of rHMPV-SHs. Respiratory symptoms and shedding of challenge virus were assessed. Neutralizing antibody responses, serum immunoglobulin G and A, and nasal wash specimen immunoglobulin A antibody responses to the HMPV F protein were also measured. Induction of nasal cytokines was assessed with electrochemiluminescence assays. RESULTS: Nine subjects (43%) were infected with challenge virus as determined by virus detection and/or ≥4-fold rise in serum antibody titers. Peak viral shedding occurred on days 7-9 after infection. Four weeks after inoculation, 35% of subjects had any antibody response. Six of 9 infected subjects had respiratory symptoms, and 3 had headache after inoculation. Cytokine patterns differed considerably between subjects with similar illness severity and viral shedding. CONCLUSIONS: The rHMPV-SHs virus is infectious and is a suitable parent virus for development of live-attenuated HMPV vaccine candidates. Clinical Trials Registration. NCT01109329.
BACKGROUND:Human metapneumovirus (HMPV) causes lower respiratory tract infections in young children. rHMPV-SHs is a recombinant HMPV (rHMPV) based on a biologically derived wild-type HMPV strain. We characterized its infectivity and immunogenicity in healthy adults to determine whether it would be suitable for use as the parent virus for the development of live attenuated rHMPV vaccines. METHODS: Twenty-one healthy adults were inoculated intranasally with 10(6) plaque-forming units of rHMPV-SHs. Respiratory symptoms and shedding of challenge virus were assessed. Neutralizing antibody responses, serum immunoglobulin G and A, and nasal wash specimen immunoglobulin A antibody responses to the HMPV F protein were also measured. Induction of nasal cytokines was assessed with electrochemiluminescence assays. RESULTS: Nine subjects (43%) were infected with challenge virus as determined by virus detection and/or ≥4-fold rise in serum antibody titers. Peak viral shedding occurred on days 7-9 after infection. Four weeks after inoculation, 35% of subjects had any antibody response. Six of 9 infected subjects had respiratory symptoms, and 3 had headache after inoculation. Cytokine patterns differed considerably between subjects with similar illness severity and viral shedding. CONCLUSIONS: The rHMPV-SHs virus is infectious and is a suitable parent virus for development of live-attenuated HMPV vaccine candidates. Clinical Trials Registration. NCT01109329.
Authors: François Freymouth; Astrid Vabret; Loic Legrand; Nicolas Eterradossi; Françoise Lafay-Delaire; Jacques Brouard; Bernard Guillois Journal: Pediatr Infect Dis J Date: 2003-01 Impact factor: 2.129
Authors: John V Williams; Paul A Harris; Sharon J Tollefson; Lisa L Halburnt-Rush; Joyce M Pingsterhaus; Kathryn M Edwards; Peter F Wright; James E Crowe Journal: N Engl J Med Date: 2004-01-29 Impact factor: 91.245
Authors: Kawsar R Talaat; Ruth A Karron; Philana H Liang; Bridget A McMahon; Catherine J Luke; Bhagvanji Thumar; Grace L Chen; Ji-Young Min; Elaine W Lamirande; Hong Jin; Kathy L Coelingh; George W Kemble; Kanta Subbarao Journal: Influenza Other Respir Viruses Date: 2012-03-14 Impact factor: 4.380
Authors: Teresa C T Peret; Guy Boivin; Yan Li; Michel Couillard; Charles Humphrey; Albert D M E Osterhaus; Dean D Erdman; Larry J Anderson Journal: J Infect Dis Date: 2002-05-03 Impact factor: 5.226
Authors: B G van den Hoogen; J C de Jong; J Groen; T Kuiken; R de Groot; R A Fouchier; A D Osterhaus Journal: Nat Med Date: 2001-06 Impact factor: 53.440
Authors: Carmen L Charlton; Esther Babady; Christine C Ginocchio; Todd F Hatchette; Robert C Jerris; Yan Li; Mike Loeffelholz; Yvette S McCarter; Melissa B Miller; Susan Novak-Weekley; Audrey N Schuetz; Yi-Wei Tang; Ray Widen; Steven J Drews Journal: Clin Microbiol Rev Date: 2018-12-12 Impact factor: 26.132
Authors: Jennifer L Lenahan; Janet A Englund; Joanne Katz; Jane Kuypers; Anna Wald; Amalia Magaret; James M Tielsch; Subarna K Khatry; Stephen C LeClerq; Laxman Shrestha; Mark C Steinhoff; Helen Y Chu Journal: Emerg Infect Dis Date: 2017-08 Impact factor: 6.883